The unfortunate events surrounding TeGenero's TGN 1412 study in the UK have only reinforced the importance of keeping an open line for safety communication with patients. Most patients taking part in clinical research are exposed to a drug without a well-established safety profile. For these volunteers, BINTO represents a critical risk management strategy to ensure they can rapidly benefit from new safety knowledge after longer term outcomes have been observed in a larger number of patients.
BINTO is an independent service that actively maintains contact with patients both during AND after their participation in a clinical trial. BINTO was established in response to difficulties faced by major pharmaceutical companies to (1) establish safety outcomes in a large number of their clinical trial patients, and (2) communicate safety update information to patients exposed to their experimental drugs. BINTO is the only provider of active patient tracking services for clinical trials, and our process for maintaining contact while protecting patient anonymity is covered by multiple US and international patents pending.
BINTO follows data management and data protection procedures that exceed standards established by HIPAA in the United States and the European Privacy Directive in the European Union. We regularly audit compliance with other privacy legislation in other countries where BINTO service is offered, including South East Asia, Eastern Europe and Australia. Patient details are not distributed to any other party. In fact, nobody - not even our staff - can search our patient database... a patient passcode or unique study number is required before a record can even be viewed.
STAFF AND FACILITIES
BINTO maintains facilities in the US and UK supporting multilingual inbound and outbound call center capability for up to 100 staff at any one time. We maintain strict practices for staff screening and training, and only employ personnel with a life sciences background to handle patient contact.